Trial Profile
Open Label Phase II Study on Glufosfamide Administered as a 60 Minute Infusion Every 3 Weeks in Advanced Non Small Cell Lung Cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Oct 2011
Price :
$35
*
At a glance
- Drugs Glufosfamide (Primary)
- Indications Lung cancer; Non-small cell lung cancer
- Focus Therapeutic Use
- 23 Jul 2008 Planned patient is now 32 as reported by ClinicalTrials.gov.
- 18 Sep 2005 New trial record.